beta

TTPH

Tetraphase Pharmaceuticals, Inc.

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Tetraphase Pharmaceuticals, Inc. engages in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also engages in the development of product candidate, eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.

Market Cap: 8.06 Million

Primary Exchange: NASDAQ

Website: http://www.tphase.com

Shares Outstanding: 7.26 Million

Float: 7.14 Million

Dividend: (%)

Beta: 1.30761533523832

Sector: Health Technology

Industry: Pharmaceuticals: Other

Ethical Flags

Longest drawdown: 1196 trading days

From: 2015-07-16 To: 2020-04-07

Lowest Point:

Tetraphase Pharmaceuticals Highlights Data at Upcoming American Society for Microbiology Microbe 2019 Annual Meeting

via: Business Wire at 2019-06-13 03:00:00:000

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced that new data will be presented at the American Society for Microbiology (ASM) Microbe… read more...

Tetraphase down 4% after hours on downsizing plan

via: SeekingAlpha at 2019-06-12 12:45:38:000

Aimed at maximizing the commercial opportunity for XERAVA (eravacycline), Tetraphase Pharmaceuticals (NASDAQ: TTPH ) will eliminate its internal research function, a move expected to save about $8M a year. More news on: Tetraphase Pharmaceuticals, Inc., Healthcare stocks news, Stocks on th… read more...

Tetraphase Pharmaceuticals Announces Corporate Reorganization Aimed at Maximizing XERAVA(TM) (Eravacycline) Commercial Opportunity

via: Business Wire at 2019-06-12 12:01:00:000

Company to Eliminate Internal Research Function and Explore Pipeline Out-licensing Opportunities to Focus the Companys Resources on XERAVA Commercial Success Workforce and R&D Expense Reduction Expected to Result in Annualized Savings of Approximately $8 Million … read more...

Tetraphase up 11% on retrospective Xerava data

via: SeekingAlpha at 2019-06-10 10:09:41:000

Nano cap Tetraphase Pharmaceuticals ( TTPH +11% ) is up on below-average volume in response to results from three studies that support the value proposition of antibiotic XERAVA (eravacycline), approved in the U.S. in April 2018 for the treatment of complicated intra-abdominal infections… read more...

Tetraphase up 11% on retrospective Xerava data

via: SeekingAlpha at 2019-06-10 10:09:41:000

Nano cap Tetraphase Pharmaceuticals ( TTPH +11% ) is up on below-average volume in response to results from three studies that support the value proposition of antibiotic XERAVA (eravacycline), approved in the U.S. in April 2018 for the treatment of complicated intra-abdominal infections… read more...

Tetraphase Pharmaceuticals Announces New XERAVA(TM) (eravacycline) Data at the 39th Annual Surgical Infection Society Meeting

via: Business Wire at 2019-06-10 03:00:00:000

-Study Examines Microbiology and Hospitalization Outcomes Among Complicated Intra-Abdominal Infection Patients- -Data Underscore XERAVAs Role as an Empiric Treatment Option for Patients With Complicated Intra-Abdominal Infections- Tetraphase Pharmaceuticals, Inc. (NASDA… read more...

Tetraphase Pharmaceuticals Announces New XERAVA(TM) (eravacycline) Data at the 39th Annual Surgical Infection Society Meeting

via: Business Wire at 2019-06-10 03:00:00:000

-Study Examines Microbiology and Hospitalization Outcomes Among Complicated Intra-Abdominal Infection Patients- -Data Underscore XERAVAs Role as an Empiric Treatment Option for Patients With Complicated Intra-Abdominal Infections- Tetraphase Pharmaceuticals, Inc. (NASDA… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud